Large pharma companies are responding to margin pressure by pouring capital into oncology and biosimilars. Your business doesn’t have that option — and it doesn’t need it. But the underlying pressure driving that shift is exactly the same pressure squeezing your portfolio, and understanding it points to a very achievable strategic move.
The Pressure Is Real, and It’s Not Slowing Down
Price erosion in mature, crowded generic molecules has continued through 2025 into early 2026, with high single-digit annual declines in several categories. For manufacturers and brands built primarily around standard oral solids sold on price, this has meant uneven revenue and persistent margin compression.
Growth Is Real, But It’s Concentrated
India’s domestic pharmaceutical market exceeded ₹2.4 lakh crore in 2025, with value growth around 7-8%. That headline number sounds healthy — but it masks an uneven distribution. Large-volume therapies under the National List of Essential Medicines remain subject to price caps and periodic revisions, while the faster value growth is concentrated in chronic and specialty segments.
| Segment Type | Growth Pattern | Pricing Power |
|---|---|---|
| Large-volume essential medicines | Slow, capped by regulation | Low |
| Chronic therapy categories | Faster, sustained growth | Moderate to strong |
| Specialty/differentiated formats | Highest growth concentration | Strongest |
What “Specialty” Means for a PCD or Marketing Company
For a large pharmaceutical company, diversifying into specialty means oncology, biosimilars, or rare disease therapies — categories requiring clinical development, complex manufacturing, and regulatory investment far beyond what a PCD or marketing company can realistically pursue.
But the strategic logic still applies to your business, just scaled to what’s actually accessible through third-party manufacturing:
A Practical Framework: Don’t Replace, Diversify
This isn’t an argument for abandoning your generic portfolio — standard generics remain a legitimate, stable-volume revenue base, and most successful PCD businesses will always carry some. The point is avoiding over-dependence on the segment with the least pricing power.
A more resilient portfolio structure looks something like:
- Core generics — stable volume, price-competitive, foundational revenue
- One or two chronic-therapy liquid orals — steadier margins, repeat-purchase behaviour
- A specialty dosage form (nasal spray, nutraceutical) — meaningfully better margins, lower competitive density
View manufacturing details for azithromycin-oral-solution
Where to Start
If your portfolio is currently concentrated in standard generic tablets and syrups, the lowest-friction diversification move is typically a nutraceutical like Vitamin D3 — see our Nutraceutical & Vitamin D3 guide — since it shares liquid-manufacturing infrastructure with products you may already carry, with a shorter regulatory path than a new pharma SKU. A nasal spray (see our specialist guide) is a strong second step once you’re ready for a slightly more technical specialty format.
How Saar Biotech Supports Portfolio Diversification
Because we manufacture across liquid orals, nasal sprays, and nutraceuticals under one WHO-GMP roof, brand owners working with us can expand into a specialty category without switching manufacturers or re-establishing a quality relationship from scratch. For our 2100+ partner brands, this typically means a faster, lower-friction path to adding a second or third product category to an existing portfolio.
Conclusion
The pressure squeezing large pharma’s generic margins is the same pressure sitting underneath your business — it’s just visible at a different scale. You don’t need an oncology pipeline to respond to it. You need a portfolio that isn’t entirely dependent on the category with the least pricing power, and specialty dosage forms are the most accessible way to build that for a PCD or marketing company.
Ready to explore adding a specialty product to your portfolio?